A Systematic Review to Assess the Impact of Non-Adherence to Treatments on Health Care Cost in Chronic Myeloid Leukemia

Abstract

Current data suggest that melanoma-related HCRU (hospice visits and hospitalization) is lower among ipilimumab patients than those receiving other approved treatments. Future analyses will present data for longer follow up and larger sample size.